Overcoming hurdles: Challenges and advancements in SMEDDS production

This comprehensive review delves into the intricate process required for developing and manufacturing Self-Microemulsifying Drug Delivery Systems (SMEDDS), emphasizing the crucial aspects essential for ensuring their efficacy and safety. It discusses the significance of various considerations, including production techniques, stringent adherence to quality assurance protocols, meticulous formulation optimization, and unwavering regulatory compliance. Specialized homogenization equipment, such as high-shear mixers and ultrasonicators, is highlighted for their pivotal role in achieving formulation uniformity and stability. Additionally, the necessity of thorough documentation throughout the manufacturing process, encompassing quality control data analysis of Critical Quality Attributes (CQAs), is underscored for regulatory approval. Excipient selection and optimization are identified as pivotal factors, requiring meticulous evaluation to ensure compatibility with the drug and stability over the intended shelf life, while also adhering to regulatory standards and Good Manufacturing Practices (cGMP). Furthermore, the review stresses the importance of carefully considering process parameters when scaling up SMEDDS production to maintain consistency, reproducibility, and meet increasing demand. Robust validation of manufacturing processes and equipment is deemed essential for ensuring reliability and scalability. By integrating these considerations, researchers and industry experts can produce high-quality SMEDDS formulations that not only enhance drug delivery but also improve patient outcomes, ultimately advancing pharmaceutical innovation and patient care.